HC Wainwright Reaffirms Buy Rating for Gossamer Bio (NASDAQ:GOSS)

HC Wainwright reaffirmed their buy rating on shares of Gossamer Bio (NASDAQ:GOSS) in a report published on Monday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright also issued estimates for Gossamer Bio’s Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($0.18) EPS, FY2027 earnings at ($0.01) EPS and FY2028 earnings at $0.28 EPS.

Separately, Wedbush reissued an “outperform” rating and issued a $4.00 price objective on shares of Gossamer Bio in a report on Tuesday, August 13th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $9.20.

Gossamer Bio Stock Down 5.6 %

Shares of NASDAQ:GOSS opened at $0.77 on Monday. The company’s 50-day moving average is $0.94 and its 200 day moving average is $0.86. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. Gossamer Bio has a fifty-two week low of $0.50 and a fifty-two week high of $1.60.

Gossamer Bio (NASDAQ:GOSS) last released its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. The company had revenue of $9.48 million for the quarter, compared to the consensus estimate of $4.52 million. Equities analysts forecast that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in GOSS. The Manufacturers Life Insurance Company lifted its holdings in shares of Gossamer Bio by 24.2% in the third quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock worth $380,000 after buying an additional 74,920 shares in the last quarter. GSA Capital Partners LLP purchased a new stake in Gossamer Bio in the 3rd quarter worth approximately $67,000. US Bancorp DE purchased a new position in shares of Gossamer Bio during the 3rd quarter valued at $39,000. Sequoia Financial Advisors LLC increased its holdings in shares of Gossamer Bio by 26.7% in the third quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock worth $117,000 after purchasing an additional 25,000 shares during the period. Finally, Algert Global LLC bought a new position in shares of Gossamer Bio in the second quarter worth $75,000. Institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.